Alport AC (1927): Hereditary familial congenital haemorrhagic nephritis. Br Med J 1927,1, 504-506
Anderson S, Rennke HG, Brenner BM (1986): Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77, 1993-2000
Antignac C. (1995): Molecular genetics of basement membranes: The paradigm of Alport syndrome. Kidney Int 49, 29-33
Antignac C, Heidet L (1996): Mutations in Alport syndrome associated with diffuse esophageal leiomyomatosis. Contrib Nephrol 117, 172-182
Atkin CL, Gregory MC, Border WA: Alport syndrome. In: Diseases of the Kidney, Band 4, hrsg. v. Schrier RW, Gottschalk CW, Little Brown, Boston 1988, 617-641
Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC, Gregory MC, Skolnick MH, Atkin CL, Tryggvason K (1990): Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 248, 1224-1227
Bland JM, Altman DG (2004): The logrank test. BMJ 328, 1073
Boutaud A, Borza DB, Bondar O, Gunwar S, Netzer KO, Singh N, Ninomiya Y, Sado Y, Noelken ME, Hudson BG (2000): Type IV collagen of the glomerular basement membrane. Evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains. J Biol Chem 275, 30716-30724
Callís L, Vila A, Carrera M, Nieto J (1999): Long-term effects of cyclosporine A in Alport
´s syndrome. Kidney Int 55, 1051-1056
Charbit M, Gubler MC, Dechaux M, Gagnadoux MF, Grünfeld JP, Niaudet P (2007):
Cyclosporine therapy in patients with Alport syndrome. Pediatr Nephrol 22, 57-63
Choi J, Na K, Bae S, Roh G (2005): Anterior lens capsule abnormalities in Alport syndrome. Korean J Ophthalmol 19, 84-89
Cohen EP, Lemann Jr J (1996): In hereditary nephritis angiotension-converting enzyme inhibition decreases proteinuria and may slow the rate of progression. Am J Kidney Dis 27, 199-203
Conlon PJ, Butterly D, Albers F, Rodby R, Gunnells JC, Howell DN (1995): Clinical and pathologic features of familial focal segmental glomerulosclerosis. Am J Kidney Dis 26, 34-40
Cosgrove D, Rodgers K, Meehan D, Miller C, Bovard K, Gilroy A, Gardner H, Kotelianski V, Gotwals P, Amatucci A et al. (2000): Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 157, 1649-1659
Dahan K, Heidet L, Zhou J, Mettler G, Leppig KA, Proesmans W, David A, Roussel B, Mongeau JG, Gould JM et al. (1995): Smooth muscle tumors associated with X-linked Alport syndrome: carrier detection in females. Kidney Int 48, 1900-1906
Feingold J, Bois E, Chompret A, Broyer M, Gubler MC, Grünfeld JP (1985): Genetic heterogeneity of Alport syndrome. Kidney Int 27, 672-677
Flinter FA, Cameron JS, Chantler C, Houston I, Bobrow M (1988): Genetics of classic Alport's syndrome. Lancet 1988,2, 1005-1007
Frei U, Schober-Halstenberg H-J (2005/2006): Nierenersatztherapie in Deutschland.
QuaSi-Niere Jahresbericht Berlin, http://www.bundesverband-niere.de/files/QuaSi-Niere-Bericht_2005-2006.pdf
García Torres R, Guarner V (1983): Leiomyomatosis of the esophagus, tracheo-bronchi and genitals associated with Alport type hereditary nephropathy: a new syndrome. Rev Gastroenterol Mex 48, 163-170
Gregory MC, Terreros DA, Barker DF, Fain PN, Denison JC, Atkin CL (1996): Alport syndrome-clinical phenotypes, incidence and pathology. Contrib Nephrol 117, 1-28 Gross O, Weber M: Von der Molekulargenetik des Alport-Syndroms zu Prinzipien der Organprotektion bei chronischen Nierenerkrankungen. In: Medizinische Klinik, Band 12, hrsg. v. Ertl G, Fölsch UR, Köbberling J, Märker-Herrmann E, Schölmerich J, Schultze-Werninghaus G, Trümper L, Weber M, Urban & Vogel, München 2005, 826-831
Gross O, Kashtan CE (2009): Treatment of Alport syndrome: beyond animal models.
Kidney Int 76; 599-603
Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M (2002): Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transplant 17, 1218-1227
Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M (2003 a): Novel COL4A4 splice defect and in-frame deletion in a large consanguine family as a genetic link between benign familial haematuria and autosomal Alport syndrome. Nephrol Dial Transplant 18, 1122-1127
Gross O, Beirowski B, Koepke ML, Kuck J, Reiner M, Addicks K, Smyth N, Schulze-Lohoff E, Weber M (2003 b): Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 63, 438-446
Gross O, Koepke M-L, Weber M (2004 a): Alport Syndrom und familiäre benigne Hämaturie: Eine Übersicht über hereditäre Erkrankungen des Typ IV Kollagens der Gefäßbasalmembranen. Nieren- und Hochdruckkrankh 7, 348-356
Gross O, Schulze-Lohoff E, Koepke ML, Beirowski B, Addicks K, Bloch W, Smyth N, Weber M (2004 b): Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 19, 1716-1723 Gross O, Koepke ML, Beirowski B, Schulze-Lohoff E, Segerer S, Weber M (2005):
Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688. Kidney Int 68, 456-463
Gross O, Girgert R, Beirowski B, Kretzler M, Kang HG, Kruegel J, Miosge N, Busse AC, Segerer S, Vogel WF et al. (2010): Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease. Matrix Biol 29, 346-356
Grünfeld JP (1985): The clinical spectrum of hereditary nephritis. Kidney Int 27, 83-92 Gubler MC (2008): Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol 4, 24-37
Gubler MC, Antignac C, Deschênes G, Knebelmann B, Hors-Cayla MC, Grünfeld JP, Broyer M, Habib R (1993): Genetic, clinical, and morphologic heterogeneity in Alport's syndrome. Adv Nephrol Necker Hosp 22, 15-35
Gunwar S, Ballester F, Noelken ME, Sado Y, Ninomiya Y, Hudson BG (1998):
Glomerular basement membrane. Identification of a novel disulfide-cross-linked network of
α
3,α
4, andα
5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome. J Biol Chem 273, 8767-8775Harvey SJ, Zheng K, Sado Y, Naito I, Ninomiya Y, Jacobs RM, Hudson BG, Thorner PS (1998): Role of distinct type IV collagen networks in glomerular development and function. Kidney Int 54, 1857-1866
Harvey SJ, Mount R, Sado Y, Naito I, Ninomiya Y, Harrison R, Jefferson B, Jacobs R, Thorner PS (2001): The inner ear of dogs with X-linked nephritis provides clues to the pathogenesis of hearing loss in X-linked Alport syndrome. Am J Pathol 159, 1097–1104
Heidet L, Cai Y, Sado Y, Ninomiya Y, Thorner P, Guicharnaud L, Boye E, Chauvet V, Solal LC, Beziau A et al. (1997): Diffuse leiomyomatosis associated with X-linked Alport syndrome: extracellular matrix study using immunohistochemistry and in situ hybridization. Lab Invest 76, 233-243
Heidet L, Arrondel C, Forestier L, Cohen-Solal L, Mollet G, Gutierrez B, Stavrou C, Gubler MC, Antignac C (2001): Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome J Am Soc Nephrol. 12, 97-106
Heikkilä P, Soininen R: The type IV collagen family. In: Molecular Pathology and Genetics of Alport Syndrome, hrsg. v. Tryggvason K, Karger, Basel 1996, 105-129 Hertz JM (2009): Alport syndrome. Molecular genetic aspects. Dan Med Bull 56, 105-152
Hinglais N, Grünfeld JP, Bois E (1972): Characteristic ultrastructural lesion of the glomerular basement membrane in progressive hereditary nephritis (Alport's syndrome). Lab Invest 27, 473-487
Hostikka SL, Eddy RL, Byers MG, Höyhtyä M, Shows TB, Tryggvason K (1990):
Identification of a distinct type IV collagen alpha chain with restricted kidney distribution and assignment of its gene to the locus of X chromosome-linked Alport syndrome. Proc Natl Acad Sci USA 87, 1606-1610
Hudson BG (2004): The molecular basis of Goodpasture and Alport syndromes:
beacons for the discovery of the collagen IV family. J Am Soc Nephrol 15, 2514-2527 Hudson BG, Reeders ST, Tryggvason K (1993): Type IV collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem 268, 26033-26036
Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG (2003): Alport's syndrome, Goodpasture's syndrome and type IV collagen. N Engl J Med 348, 2543-2556
Imai E, Takabatake Y, Mizui M, Isaka Y (2004): Gene therapy in renal diseases. Kidney Int 65, 1551-1555
Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F et al. (1997): Autosomal dominant Alport syndrome linked to the type IV collage alpha 3 and alpha 4 genes (COL4A3 and COL4A4). Nephrol Dial Transplant 12, 1595-1599
Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F et al. (2000): X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 11, 649-657 Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F et al. (2003): X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a
"European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol 14, 2603-2610
Kalluri R, Shield CF, Todd P, Hudson BG, Neilson EG (1997): Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 99, 2470-2478
Kalluri R, Gattone VH 2nd, Hudson BG (1998): Identification and localization of type IV collagen chains in the inner ear cochlea. Connect Tissue Res 37, 143-150
Kashtan, CE (1998): Alport Syndrome and Thin Glomerular Basement Membrane Disease. J Am Soc Nephrol 9, 1736-1750
Kashtan CE (2000): Alport syndrome: renal transplantation and donor selection. Ren Fail 22, 765-768
Kashtan CE: Collagen IV-Related Nephropathies (Alport Syndrome and Thin Basement Membrane Nephropathy). In: Gene Reviews, hrsg. v. Pagon RA, Bird TD, Dolan CR, Stephens K, o. Verl., Seattle, 2001
Kashtan CE (2003): Alport Syndrome and Thin Basement Membrane Nephropathy:
Diseases Arising from Mutations in Type IV Collagen. Saudi J Kidney Dis Transpl 14, 276-289
Kashtan CE (2004): Familial hematuria due to type IV collagen mutations: Alport syndrome and thin basement membrane nephropathy. Curr Opin Pediatr 16, 177-181 Kashtan CE (2007): Alport syndrome and the X-chromosome: implications of a diagnosis of Alport syndrome in females. Nephrol Dial Transplant 22, 1499-1505
Kashtan CE, Michael AF (1996): Alport syndrome. Kidney Int 50, 1445-1463
Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C (2012): Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol (http://www.springerlink.com/content/j3337878423r7t25/fulltext.html)
Knebelmann B, Forestier L, Drouot L, Quinones S, Chuet C, Benessy F, Saus J, Antignac C (1995): Splice-mediated insertion of an Alu sequence in the COL4A3 mRNA causing autosomal recessive Alport syndrome. Hum Mol Genet 4, 675-679
Koepke ML, Weber M, Schulze-Lohoff E, Beirowski B, Segerer S, Gross O (2007):
Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Nephrol Dial Transplant 22, 1062-1069
Kunz R, Friedrich C, Wolbers M, Mann JF (2008): Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148, 30-48
Lagona E, Tsartsali L, Kostaridou S, Skiathitou A, Georgaki E, Sotsiou F (2008): Skin biopsy for the diagnosis of Alport syndrome. Hippokratia 12, 116-118
Lemmink HH, Mochizuki T, van den Heuvel LP, Schroeder CH, Barientos A, Monnens LA, van Oost BA, Brunner HG, Reeders ST, Smeets HJM (1994): Mutations in the type IV collagen α3 (COL4A3) gene in autosomal recessive Alport syndrome. Hum Mol Genet 3, 1269 -1273
Lemmink HH, Schröder CH, Monnens LA, Smeets HJ (1997): The clinical spectrum of type IV collagen mutations. Hum Mutat 9, 477-499
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I (2001): Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345, 851–
860
Longo I, Porcedda P, Mari F, Giachino D, Meloni I, Deplano C, Brusco A, Bosio M, Massella L, Lavoratti G (2002): COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int 61, 1947-1956
Longo I, Scala E, Mari F, Caselli R, Pescucci C, Mencarelli MA, Speciale C, Giani M, Bresin E, Caringella DA et al. (2006): Autosomal recessive Alport syndrome: an in-depth clinical and molecular analysis of five families. Nephrol Dial Transplant 21, 665-671
Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S et al. (2008): Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547-553
Marcocci E, Uliana V, Bruttini M, Artuso R, Silengo MC, Zerial M, Bergesio F, Amoroso A, Savoldi S, Pennesi M (2009): Autosomal dominant Alport syndrome: molecular analysis of the COL4A4 gene and clinical outcome. Nephrol Dial Transplant 24, 1464-1471
Mazzucco G, Barsotti P, Muda AO, Fortunato M, Mihatsch M, Torri-Tarelli L, Renieri A, Faraggiana T, De Marchi M, Monga G (1998): Ultrastructural and immunohistochemical findings in Alport's syndrome: a study of 108 patients from 97 Italian families with particular emphasis on COL4A5 gene mutation correlations. J Am Soc Nephrol 9, 1023-1031
McCoy RC, Johnson HK, Stone WJ, Wilson CB (1982): Absence of nephritogenic GBM antigen(s) in some patients with hereditary nephritis. Kidney Int 21, 642-652
Miner JH (1999 a): Alport Syndrome with Diffuse Leiomyomatosis. When and when not? Am J Pathol 154, 1633–1635
Miner JH (1999 b) Renal basement membrane components. Kidney Int 56, 2016-2024 Mochizuki T, Lemmink HH, Mariyama M, Antignac C, Gubler MC, Pirson Y, Verellen-Dumoulin C, Chan B, Schroeder CH, Smeets HJM, et al. (1994): Identification of mutations in the α3(IV) and α4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 8, 77-82
Mothes H, Heidet L, Arrondel C, Richter KK, Thiele M, Patzer L, Sado Y, Gubler MC, Antignac C, Scheele J (2002): Alport syndrome associated with diffuse leiomyomatosis:
COL4A5-COL4A6 deletion associated with a mild form of Alport nephropathy. Nephrol Dial Transplant 17, 70–74
Nagel M, Nagorka S, Gross O (2005): Novel COL4A5, COL4A4, and COL4A3 mutations in Alport syndrome. Hum Mutat 26, 60
National Kidney Foundation (2002): K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39, 1-266 Osterby R (1997): Renal changes in the diabetic kidney. Nephrol Dial Transplant 12, 1282-1283
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P (2001):
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345, 870-878
Perrin D, Jungers P, Grunfeld JP, Delons S, Noel LH, Zenatti C (1980): Perimacular changes in Alport's syndrome. Clin Nephrol 13, 163-167
Pichler RH, de Boer IH (2010): Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease. Curr Diab Rep 10, 297-305
Pirson Y (1999): Making the diagnosis of Alport's syndrome. Kidney Int 56, 760-775 Remuzzi G, Schieppati A, Ruggenenti P (2002): Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 346, 1145-1151
Rüster C, Wolf G (2006): Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 17, 2985–2991
Savige J, Rana K, Tonna S, Buzza M, Dagher H, Wang YY (2003): Thin basement membrane nephropathy. Kidney Int 64, 1169-1178
Savige J, Liu J, DeBuc DC, Handa JT, Hageman GS, Wang YY, Parkin JD, Vote B, Fassett R, Sarks S et al. (2010): Retinal basement membrane abnormalities and the retinopathy of Alport syndrome. Invest Ophthalmol Vis Sci 51, 1621-1627
Siragy HM, Carey RM (2010): Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 31, 541-550
Statistisches Bundesamt: https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/
Bevoelkerung/Sterbefaelle/Tabellen/LebenserwartungBundeslaenderWeiblich.html
Temme J, Peters F, Lange K, Pirson Y, Heidet L, Torra R, Grunfeld JP, Weber M, Licht C, Müller GA, et al. (2012): Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int 81, 779-83
Tishler PV (1979): Healthy female carriers of a gene for the Alport syndrome:
importance for genetic counseling. Clin Genet 16, 291-294
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997):
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy.
Lancet 349, 1857-1863
The National Collaborating Centre for Chronic Conditions: Chronic kidney disease:
national clinical guideline for early identification and management in adults in primary and secondary care. (NICE Clinical Guidelines, No. 73) NCC-CC, London 2008
Tryggvason K (1995): Molecular properties and diseases of collagens. Kidney Int Suppl 49, 24-28
Tryggvason K: Mutations in type IV collagen genes and Alport phenotypes. In:
Molecular Pathology and Genetics of Alport Syndrome, hrsg. v. Tryggvason K, Karger, Basel 1996, 154-171
Utsumi K, Katsura K, Iino Y, Katayama Y (2012): Blood pressure control in patients with chronic kidney disease. J Nihon Med Sch 79,111-114
Verdecchia P, Angeli F, Mazzotta G, Martire P, Garofoli M, Gentile G, Reboldi G (2010):
Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis 4, 193-200 Weber M (1992): Basement membrane proteins. Kidney Int 41, 620-628
Wing AJ, Brunner FP (1989): Twenty-three years of dialysis and transplantation in Europe: Experiences of the EDTA registry. Am J Kidney Dis 14, 341 -346
Wolf G, Ritz E (2005): Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int 67, 799 –812
Wutz A, Gribnau J (2007): X inactivation Xplained. Curr Opin Genet Dev 17, 387-393 Zeisberg M, Khurana M, Rao VH, Cosgrove D, Rougier JP, Werner MC, Shield CF 3rd, Werb Z, Kalluri R (2006): Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PloS Med 3